

SEQUENCE LISTING

<110> BUSCHLE, MICHAEL  
HABEL, ANDRE  
FRITZ, JORG  
PRINZ, KARIN  
LINGNAU, KAREN

<120> IMPROVED VACCINES

<130> SONN:076US

<140> UNKNOWN

<141> 2005-09-23

<150> PCT/EP2004/003002

<151> 2004-03-22

<150> EP 03450072.8

<151> 2003-03-24

<150> EP 03450084.3

<151> 2003-04-11

<150> EP 03450171.89

<151> 2003-07-11

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>

<221> MOD\_RES

<222> (1)..(9)

<223> X = any positively charged amino acid

<400> 1

Xaa Glx Xaa Glx Glx Xaa Glx Xaa

1

5

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>

<221> MOD\_RES

<222> (1)..(10)  
 <223> X = any positively charged amino acid  
  
 <400> 2  
 Xaa Glx Xaa Glx Glx Glx Glx Xaa Glx Xaa  
       1                              5                              10  
  
 <210> 3  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
       Peptide  
  
 <220>  
 <221> MOD\_RES  
 <222> (1)..(11)  
  
 <400> 3  
 Xaa Glx Xaa Glx Glx Glx Glx Glx Xaa Glx Xaa  
       1                              5                              10  
  
 <210> 4  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
       Peptide  
  
 <220>  
 <221> MOD\_RES  
 <222> (1)..(12)  
 <223> X = any positively charged amino acid  
  
 <400> 4  
 Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Xaa Glx Xaa  
       1                              5                              10  
  
 <210> 5  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
       Peptide  
  
 <220>  
 <221> MOD\_RES  
 <222> (1)..(13)  
 <223> X = any positively charged amino acid  
  
 <400> 5  
 Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Xaa Glx Xaa

1	5	10
---	---	----

<210> 6  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 6  
 Lys Leu Lys Leu Leu Leu Leu Lys Leu Lys  
 1 5 10

<210> 7  
 <211> 26  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 7  
 Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys  
 1 5 10 15  
 Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys  
 20 25

<210> 8  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 8  
 Gly Leu Cys Thr Leu Val Ala Met Leu  
 1 5

<210> 9  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 9  
 Ile Ala Ser Asn Glu Asn Met Glu Thr Met  
 1 5 10

<210> 10  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 10  
Thr Met Leu Tyr Asn Lys Met Glu Phe  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 11  
Ser Ser Ile Ala Ala Gln Asp Ala Leu  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 12  
Val Thr Ile Leu Asn Leu Ala Leu Leu  
1 5

<210> 13  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 13  
Lys Phe Pro Gly Gly Gly Gln Ile Val Gly Gly Val Tyr Leu Leu Pro  
1 5 10 15

Arg Arg Gly Pro Arg Leu  
20

<210> 14

<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 14  
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr  
1 5 10

<210> 15  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 15  
Asp Leu Met Gly Tyr Ile Pro Ala Val  
1 5

<210> 16  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 16  
Cys Ile Asn Gly Val Cys Trp Thr Val  
1 5

<210> 17  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 17  
His Met Trp Asn Phe Ile Ser Gly Ile Gln Tyr Leu Ala Gly Leu Ser  
1 5 10 15

Thr Leu Pro Gly Asn Pro Ala  
20

<210> 18  
<211> 9  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 18

Tyr Met Asp Gly Thr Met Ser Gln Val  
1 5

<210> 19

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 19

tccatgactt tcctgatgct

# SEQUENCE LISTING

<110> BUSCHLE, MICHAEL  
LINGNAU, KAREN

<120> USE OF ALUM AND A TH1 IMMUNE RESPONSE INDUCING ADJUVANT  
FOR ENHANCING IMMUNE RESPONSES

<130> SONN:077US

<140> UNKNOWN

<141> 2005-09-23

<150> PCT/EP2004/003029

<151> 2004-03-22

<150> EP 03450072.8

<151> 2003-03-24

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>

<221> MOD\_RES

<222> (1)..(9)

<223> X = any positively charged amino acid

<400> 1

Xaa Glx Xaa Glx Glx Glx Xaa Glx Xaa  
1 5

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>

<221> MOD\_RES

<222> (1)..(10)

<223> X = any positively charged amino acid

<400> 2

Xaa Glx Xaa Glx Glx Glx Xaa Glx Xaa  
1 5 10

<210> 3

<211> 11

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic Peptide

<220>  
<221> MOD\_RES  
<222> (1)..(11)

<400> 3  
Xaa Glx Xaa Glx Glx Glx Glx Xaa Glx Xaa  
1 5 10

<210> 4  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic Peptide

<220>  
<221> MOD\_RES  
<222> (1)..(12)  
<223> X = any positively charged amino acid

<400> 4  
Xaa Glx Xaa Glx Glx Glx Glx Glx Xaa Glx Xaa  
1 5 10

<210> 5  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic Peptide

<220>  
<221> MOD\_RES  
<222> (1)..(13)  
<223> X = any positively charged amino acid

<400> 5  
Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Xaa Glx Xaa  
1 5 10

<210> 6  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 6

Lys Leu Lys Leu Leu Leu Leu Lys Leu Lys  
1 5 10

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 7

tccatgacit tcctgatgct

20

<210> 8

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 8

Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys  
1 5 10 15

Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys  
20 25

# SEQUENCE LISTING

<110> BUSCHLE, MICHAEL  
HABEL, ANDRE  
FRITZ, JORG  
PRINZ, KARIN  
LINGNAU, KAREN

<120> IMPROVED VACCINES

<130> SONN:076US

<140> UNKNOWN

<141> 2005-09-23

<150> PCT/EP2004/003002

<151> 2004-03-22

<150> EP 03450072.8

<151> 2003-03-24

<150> EP 03450084.3

<151> 2003-04-11

<150> EP 03450171.89

<151> 2003-07-11

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

<221> MOD\_RES

<222> (1)..(9)

<223> X = any positively charged amino acid

<400> 1

Xaa Glx Xaa Glx Glx Glx Xaa Glx Xaa

1

5

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

<221> MOD\_RES



1	5	10
---	---	----

<210> 6  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 6  
 Lys Leu Lys Leu Leu Leu Leu Lys Leu Lys  
 1 5 10

<210> 7  
 <211> 26  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 7  
 Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys  
 1 5 10 15  
 Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys  
 20 25

<210> 8  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 8  
 Gly Leu Cys Thr Leu Val Ala Met Leu  
 1 5

<210> 9  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 9  
 Ile Ala Ser Asn Glu Asn Met Glu Thr Met  
 1 5 10

<210> 10  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 10  
Thr Met Leu Tyr Asn Lys Met Glu Phe  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 11  
Ser Ser Ile Ala Ala Gln Asp Ala Leu  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 12  
Val Thr Ile Leu Asn Leu Ala Leu Leu  
1 5

<210> 13  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 13  
Lys Phe Pro Gly Gly Gly Gln Ile Val Gly Gly Val Tyr Leu Leu Pro  
1 5 10 15

Arg Arg Gly Pro Arg Leu  
20

<210> 14

<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 14  
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr  
1 5 10

<210> 15  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 15  
Asp Leu Met Gly Tyr Ile Pro Ala Val  
1 5

<210> 16  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 16  
Cys Ile Asn Gly Val Cys Trp Thr Val  
1 5

<210> 17  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 17  
His Met Trp Asn Phe Ile Ser Gly Ile Gln Tyr Leu Ala Gly Leu Ser  
1 5 10 15

Thr Leu Pro Gly Asn Pro Ala  
20

<210> 18  
<211> 9  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 18

Tyr Met Asp Gly Thr Met Ser Gln Val

1

5

<210> 19

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Primer

<400> 19

tccatgacit tcctgatgct

<210> 20

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Primer

<400> 18

tccatgacgt tcctgatg